The European Committee for Medicinal Products for Human Use issued a positive opinion of AbbVie's hepatitis C treatment, Maviret.
Here's what you should know:
1. Maviret is an eight-week, pan-genotypic, once-daily option for the treatment of hepatitis C in patients without cirrhosis and who are new to treatment of all genotypes.
2. AbbVie expects The European Commission to review Maviret and issue an opinion in the third quarter of fiscal year 2017.
3. AbbVie Executive Vice President of Research and Development and Chief Scientific Officer Michael Severino, MD, said in a release, "Maviret represents a new generation of HCV therapy and has the potential to be a shorter, 8-week option for patients living with this serious, chronic illness. Today's CHMP positive opinion takes us closer to delivering on AbbVie's mission to address continued unmet needs by bringing a new pan-genotypic option to people living with HCV in Europe."